

Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income or Loss

<i>USD in thousands, except for per share amounts</i>	Nine months ended 30 September 2023	Nine months ended 30 September 2022
Product revenue	29,800	11,060
License and other revenue	8,244	48,111
Other income	56	197
Cost of product revenue	(104,437)	(35,362)
Research and development expenses	(152,813)	(133,140)
General and administrative expenses	(58,558)	(156,520)
Operating loss	(277,708)	(265,654)
Share of net loss of joint venture	(3,983)	(1,732)
Finance income	46,383	97,299
Finance costs	(107,826)	(69,200)
Exchange rate differences	884	13,643
Gain on extinguishment of financial liabilities	-	17,800
Non-operating profit / (loss)	(64,542)	57,810
Loss before taxes	(342,250)	(207,844)
Income tax benefit	67,076	14,771
Loss for the period	(275,174)	(193,073)
Other comprehensive loss		
<i>Item that will be reclassified to profit or loss in subsequent periods:</i>		
Exchange rate differences on translation of foreign operations	(2,648)	(8,852)
Total comprehensive loss	(277,822)	(201,925)
Loss per share		
Basic and diluted loss for the period per share	(1.21)	(1.00)

Unaudited Condensed Consolidated Interim Statement of Financial Position

<i>USD in thousands</i>	30 September 2023	31 December 2022
Non-current assets		
Property, plant and equipment	235,091	220,594
Right-of-use assets	108,371	47,501
Goodwill	11,555	11,643
Other intangible assets	20,283	25,652
Contract assets	8,111	3,286
Investment in joint venture	42,035	48,568
Other long-term assets	1,957	5,780
Restricted cash	25,187	25,187
Deferred tax assets	277,838	209,496
Total non-current assets	730,428	597,707
Current assets		
Inventories	81,995	71,470
Trade receivables	21,945	32,972
Contract assets	18,514	25,370
Other current assets	36,031	32,949
Receivables from related parties	1,591	1,548
Cash and cash equivalents	68,315	66,427
Total current assets	228,391	230,736
Total assets	958,819	828,443

Unaudited Condensed Consolidated Interim Statement of Financial Position

<i>USD in thousands</i>	30 September 2023	31 December 2022
Equity		
Share capital	2,271	2,126
Share premium	1,224,844	1,058,432
Other reserves	45,411	30,582
Translation reserve	(4,090)	(1,442)
Accumulated deficit	(1,929,288)	(1,654,114)
Total equity	(660,852)	(564,416)
Non-current liabilities		
Borrowings	898,483	744,654
Derivative financial liabilities	359,861	380,232
Other long-term liability to related party	7,440	7,440
Lease liabilities	94,375	35,369
Long-term incentive plan	-	544
Contract liabilities	72,695	57,017
Deferred tax liability	63	309
Total non-current liabilities	1,432,917	1,225,565
Current liabilities		
Trade and other payables	52,662	49,188
Lease liabilities	8,579	5,163
Current maturities of borrowings	13,594	19,916
Liabilities to related parties	1,189	1,131
Contract liabilities	53,419	36,915
Taxes payable	1,721	934
Other current liabilities	55,590	54,047
Total current liabilities	186,754	167,294
Total liabilities	1,619,671	1,392,859
Total equity and liabilities	958,819	828,443

Unaudited Condensed Consolidated Interim Statements of Cash Flows

<i>USD in thousands</i>	Nine months ended 30 September 2023	Nine months ended 30 September 2022
Cash flows from operating activities		
Loss for the period	(275,174)	(193,073)
Adjustments for non-cash items:		
Gain on extinguishment of SARs liability.....	-	(4,803)
Share listing expense.....	-	83,411
Share-based payment expense.....	15,199	5,686
Depreciation and amortization.....	17,485	15,084
Impairment of other intangible assets.....	-	2,765
Loss on disposal of property, plant and equipment.....	323	-
Change in allowance for receivables.....	18,500	-
Share of net loss of joint venture.....	3,983	1,732
Finance income.....	(46,383)	(97,299)
Finance costs.....	107,826	69,200
Gain on extinguishment of financial liabilities.....	-	(17,800)
Exchange rate difference.....	(884)	(13,643)
Income tax benefit.....	(67,076)	(14,771)
Operating cash flow before movement in working capital	<hr/>	<hr/>
Increase in inventories	(226,201)	(163,511)
(Increase) / decrease in trade receivables	(10,525)	(28,401)
Increase in net liabilities with related parties	11,027	4,437
(Increase) / decrease in contract assets	15	1,188
Increase in other assets	2,031	(8,286)
Increase in trade and other payables	(15)	(10,297)
Increase / (decrease) in contract liabilities	(566)	9,884
Increase / (decrease) in other liabilities	32,182	(10,340)
	(21,737)	(29,214)
Cash used in operations	<hr/>	<hr/>
Interest received	(213,789)	(234,540)
Interest paid	46	14
Income tax paid	(30,582)	(13,072)
	(697)	(416)
Net cash used in operating activities	<hr/>	<hr/>
	(245,022)	(248,014)

Cash flows from investing activities

Acquisition of property, plant and equipment	(29,440)	(28,942)
Disposal of property, plant and equipment	133	379
Acquisition of intangible assets	(6,571)	(9,591)
Restricted cash in connection with the amended bond agreement	-	(14,914)
Net cash used in investing activities	(35,878)	(53,068)

Cash flows from financing activities

Repayments of borrowings	(97,538)	(2,206)
Repayments of principal portion of lease liabilities	(5,838)	(6,990)
Proceeds from new borrowings.....	244,908	16,537
Gross proceeds from the private placement equity offering fee.....	136,877	-
Gross private placement equity offering fee paid.....	(4,141)	-
Proceeds from warrants	6,390	-
Gross proceeds from the PIPE Financing	-	174,930
Gross PIPE Financing fees paid.....	-	(5,561)
Proceeds from the Capital Reorganization.....	-	9,827
Proceeds from loans from related parties.....	-	110,000
Net cash generated from financing activities	280,658	296,537
Decrease in cash and cash equivalents	(242)	(4,545)
Cash and cash equivalents at the beginning of the period	66,427	17,556
Effect of movements in exchange rates on cash held	2,130	(167)
Cash and cash equivalents at the end of the period	68,315	12,844